Updates in the management of dyslipidaemia in the high and very high risk individual for CV risk reduction

• Published in: Medical Journal of Malaysia
• Main Author: Rajadurai J.; Wan Ahmad W.A.; Nawawi H.; Hooi C.G.; Kiat N.W.; Ali R.M.; Omar A.F.; Kasim S.; Maskon O.; Leng D.Q.K.
• Format: Article
• Language: English
• Published: Malaysian Medical Association 2018
• Online Access: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85049363568&partnerID=40&md5=1ad79a6b76306d276c53cba792200761

Cardiovascular disease (CVD) has been the main cause of mortality and an important cause of morbidity in Malaysia for several years. To reduce global cardiovascular (CV) risk in the population, primary preventive strategies need to be implemented. Hypercholesterolaemia is one of the major risk factors for CVD. This paper is an expert review on the management of hypercholesterolemia focusing on high and very high risk individuals. In low and Intermediate risk individuals, therapeutic lifestyle changes (TLC) and a healthy lifestyle alone may suffice. In high and very high risk individuals, drug therapy in conjunction with TLC are necessary to achieve the target LDL-C levels which have been shown to slow down progression and sometimes even result in regression of atherosclerotic plaques. Statins are first-line drugs because they have been shown in numerous randomized controlled trials to be effective in reducing CV events and to be safe. In some high risk individuals, despite maximally tolerated statin therapy, target Low Density Lipoprotein Cholesterol (LDL-C) levels are not achieved. These include those with familial hypercholesterolaemia and statin intolerance. This paper discusses non-statin therapies, such as ezetimibe and the newer Proprotein convertase subtilisin/kexin type 9 Inhibitors (PCSK9-i). © 2018, Malaysian Medical Association. All rights reserved.